A Special Notice from GraMedica for Potential HyProCure® Recipients

Make Sure Your Surgeon is Using HyProCure®.

HyProCure® is the result of GraMedica's passion for creating medical products that offer better patient outcomes. It has been specifically designed to fix ankle bone displacement, a condition that leads to misaligned feet. HyProCure® represents a significant advancement in this life-changing, minimally invasive procedure.

Unfortunately, the medical market offers other implants that claim a similar purpose. However, these devices do not have the same scientific backing and more importantly, they have a higher rate of failure. Published studies show these inferior devices have higher than industry standard removal rates—nearly 40%-100%. In some cases, hospitals and surgery centers may prefer to use these devices simply due to a lower cost, or because they may be paid or reimbursed for removal.

HyProCure® is the only subtalar implant classified as a Type II extra-osseous talotarsal stabilization stent. It is backed by extensive scientific evidence from over a dozen published research studies. Simply put, because of its unique design and improved biomechanically correct function, HyProCure® is the most effective implant, with the highest success rate of any subtalar implant.

HyProCure® Facts:

• FDA cleared since 2004, HyProCure has been used by foot and ankle specialists in over 60,000 procedures in 70 countries.

• Unlike other stents that block your range of motion, HyProCure® stabilizes the foot and restores natural joint motion.

• HyProCure® is recommended for use in both pediatric and adult patients.

If you have been identified as a HyProCure® candidate, take the time to ensure your surgeon uses only the clinically proven HyProCure® stent. Each stent comes with an identification card. Please ensure you receive this card to guarantee you are receiving a HyProCure® stent.

To view published studies, please visit www.hyprocure.com/published-studies

GraMedica®